Targeted Oncology

The immune checkpoint inhibitor (ICI) nivolumab has been approved for previously treated patients with metastatic renal cell carcinoma (mRCC), based on the findings of the pivotal phase III CheckMate 025 trial [ 1 ], which demonstrated that …

The immune system encompasses a broad array of defense mechanisms against foreign threats, including invading pathogens and transformed neoplastic cells. Toll-like receptors (TLRs) are critically involved in innate immunity, serving as pattern …

Fusion proteins involving anaplastic lymphoma kinase (ALK) define a unique molecular subtype of non-small cell lung cancer (NSCLC) and can be detected in 5–7% of unselected NSCLC patients, especially in adenocarcinoma and younger patients [ 1 , 2 …

Prostate cancer (PC) is the most frequently diagnosed solid tumour among men and the third leading cause of cancer-related deaths [ 1 , 2 ]. In Europe, today only 4% of newly diagnosed patients present with metastatic disease [ 3 ]. De novo hormone …

About 50% of sarcomas have specific pathology-defining molecular alterations including mutations, fusion genes, and gene amplifications. Some of these alterations appear to be oncogenic drivers, and a subset can be utilized as targets for standard …